SOLICITATION NOTICE
66 -- Notice of Intent to Sole Source to BioFire for a GI Pathogen Detection Panel
- Notice Date
- 5/20/2021 8:33:12 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- CDC OFFICE OF ACQUISITION SERVICES ATLANTA GA 30333 USA
- ZIP Code
- 30333
- Solicitation Number
- 55345
- Response Due
- 6/3/2021 10:00:00 AM
- Archive Date
- 06/18/2021
- Point of Contact
- Zachary Perez (CTR), Martin F. Nemec, Phone: 4044985605
- E-Mail Address
-
qyk5@cdc.gov, oga2@cdc.gov
(qyk5@cdc.gov, oga2@cdc.gov)
- Description
- The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases hereby announces its intent to issue a sole source order/contract to BioFire, 515 Colorow Drive, Salt Lake City, Utah 84108. The NAICS code for this acquisition is 334516, Analytical Laboratory Instrument Manufacturing. The Centers for Diesase Control and Prevention is looking for a vendor who can supply a GI pathogen detection panel using a real time multiplex PCR system capable of detecting multiple (22) enteric pathogens in the same test. This testing format and its associated platform is proprietary to the BioFire Torch system, which is a unique platform only produced and available from BioFire. These testing kits are FDA-approved, all-in-one, and easy to use, making them highly suitable for capacity building efforts. Each test is in a sealable plastic pouch which requires minimal specimen handling, and additionally seals the specimen material inside the test pouch, sharply reducing exposure risks associated with specimen processing and disposal. Additionally, the Torch platform supports multiple types of FDA-approved testing kits which are available from BioFire, including a kit for Covid-19 testing, and are needed for continuity with state partner pathogen screening that also utilizes the BioFire platform. No competitors offer a similar testing platform, and thus would require alternative, individual testing methods for each of the 22 pathogens that are included as part of the BioFire GI panel test kits. Such alternative methods have increased cost, increased safety risk to the processing technician, increased error rates, and are not FDA-approved. This action is for supplies which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b)� and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit quotations. This is not a request for competitive quotations; however, the Government will review any/all product, capabilities, and pricing information submitted prior to the closure of this notice. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any responses should be emailed to Zachary Perez (CTR) at qyk5@cdc.gov by�June 3rd, 2021 at 1:00 P.M. ET.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/509ab01d87ea45439885add70b7323e2/view)
- Place of Performance
- Address: Atlanta, GA, USA
- Country: USA
- Country: USA
- Record
- SN06008989-F 20210522/210521201532 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |